Credit Suisse Starts Medpace (MEDP) at Outperform

September 6, 2016 7:08 AM EDT
Get Alerts MEDP Hot Sheet
Price: $28.74 --0%

Rating Summary:
    4 Buy, 2 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 22 | Down: 34 | New: 5
Trade MEDP Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Credit Suisse initiates coverage on Medpace (NASDAQ: MEDP) with a Outperform rating and a price target of $35.00.

Analyst Erin Wilson commented, "MEDP is a leading global clinical stage contract research organization (CRO), differentiated in its exclusively full-service model. It should benefit from a strong fundamental backdrop for CROs while leveraging its disciplined and scientifically-driven full-service approach, a unique competitive advantage. It should grow ahead of the industry and more profitably without meaningful capital requirements, supporting doubledigit revenue and EPS growth over the long term."

For an analyst ratings summary and ratings history on Medpace click here. For more ratings news on Medpace click here.

Shares of Medpace closed at $30.70 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities

Credit Suisse, Erin Wilson

Add Your Comment